Perspective Therapeutics Prices $175 Million Public Offering of Shares and Pre-Funded Warrants

Perspective Therapeutics (Nasdaq: PRSP) priced a public offering of 24.3 million shares and pre-funded warrants at $7.20 per share on February 3, 2026, raising approximately $175 million in gross proceeds. The offering includes 19.4 million common shares and 4.9 million pre-funded warrants, each exercisable for one common share at $0.01. The company intends to use the net proceeds for clinical development of its oncology pipeline, including its lead candidate PT-01, and for general corporate purposes. The offering is expected to close on or about February 7, 2026, subject to customary closing conditions.